BR112016013116A8 - inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas - Google Patents

inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas Download PDF

Info

Publication number
BR112016013116A8
BR112016013116A8 BR112016013116A BR112016013116A BR112016013116A8 BR 112016013116 A8 BR112016013116 A8 BR 112016013116A8 BR 112016013116 A BR112016013116 A BR 112016013116A BR 112016013116 A BR112016013116 A BR 112016013116A BR 112016013116 A8 BR112016013116 A8 BR 112016013116A8
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
pyrazolyl guanidine
atpase inhibitors
trifluoromethyl pyrazolyl
trifluoromethyl
Prior art date
Application number
BR112016013116A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016013116A2 (pt
Inventor
R Hurd Alexander
B Taylor Clarke
Wang Jian
Zhou Peng
Original Assignee
Lycera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lycera Corp filed Critical Lycera Corp
Publication of BR112016013116A2 publication Critical patent/BR112016013116A2/pt
Publication of BR112016013116A8 publication Critical patent/BR112016013116A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112016013116A 2013-12-10 2014-12-10 inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas BR112016013116A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361914085P 2013-12-10 2013-12-10
US201461979619P 2014-04-15 2014-04-15
PCT/US2014/069487 WO2015089149A1 (en) 2013-12-10 2014-12-10 Trifluoromethyl pyrazolyl guanidine f1fo-atpase inhibitors and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
BR112016013116A2 BR112016013116A2 (pt) 2017-08-08
BR112016013116A8 true BR112016013116A8 (pt) 2020-05-12

Family

ID=53371791

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016013116A BR112016013116A8 (pt) 2013-12-10 2014-12-10 inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas

Country Status (10)

Country Link
US (4) US9266839B2 (enExample)
EP (1) EP3080089B1 (enExample)
JP (1) JP6486364B2 (enExample)
CN (1) CN105899489A (enExample)
AU (1) AU2014363904B2 (enExample)
BR (1) BR112016013116A8 (enExample)
CA (1) CA2931851A1 (enExample)
IL (1) IL245930A0 (enExample)
MX (1) MX2016007445A (enExample)
WO (1) WO2015089149A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2591156T3 (es) 2010-12-08 2016-11-25 Lycera Corporation Inhibidores de F1F0-ATPasas de tipo piridonil guanidina y sus usos terapéuticos
PL2648511T3 (pl) 2010-12-08 2017-12-29 Lycera Corporation Pirazoliloguanidynowe inhibitory F1F0-ATPaz i ich zastosowania terapeutyczne
EP2866893A4 (en) 2012-06-08 2015-12-23 Lycera Corp HETEROCYCLIC GUANIDINE F1FO ATPASE INHIBITORS
US9920012B2 (en) 2012-06-08 2018-03-20 Lycera Corporation Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
WO2013185046A1 (en) 2012-06-08 2013-12-12 Lycera Corporation Saturated acyl guanid1ne for inhibition of f1f0-atpase
JP6486364B2 (ja) 2013-12-10 2019-03-20 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ トリフルオロメチルピラゾリルグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤及びその治療用途
JP2016539993A (ja) 2013-12-10 2016-12-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ Ｎ−置換ピラゾリルグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤及びその治療用途
US9815791B2 (en) 2013-12-10 2017-11-14 Lycera Corporation Alkylpyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
CN116570589B (zh) * 2023-05-30 2025-02-11 南阳理工学院 化合物Parimifasor在制备抗肿瘤药物中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977189A (en) * 1986-05-07 1990-12-11 American Cyanamid Company Substituted guanidinedicarbonyl derivatives
JPH07188197A (ja) 1993-11-17 1995-07-25 Fujisawa Pharmaceut Co Ltd オキサゾール誘導体
DE4344550A1 (de) 1993-12-24 1995-06-29 Hoechst Ag Substituierte 1-Oxo-1,2-dihydro-isochinolinoyl- und 1,1-Dioxo-2H-1,2-benzothiazinoylguanidine, Verfahrenzu ihrer Herstellung, ihre Verwendung als Medikamentt oder Diagnostikum sowie sie enthaltendes Medikamen
US7041702B1 (en) 1997-10-21 2006-05-09 Scion Pharmaceuticals, Inc. Pharmaceutically active compounds and methods of use
EP1156803A4 (en) 1999-02-09 2004-03-17 Bristol Myers Squibb Co FXA LACTAM INHIBITORS AND METHOD
US7276348B2 (en) 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
KR20020012310A (ko) 1999-07-15 2002-02-15 다께우찌 마사야쓰 복소 방향환 화합물
CA2413245A1 (en) 2000-06-30 2002-01-10 Bristol-Myers Squibb Pharma Company N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
WO2003050261A2 (en) 2001-12-10 2003-06-19 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
GB0208224D0 (en) 2002-04-10 2002-05-22 Celltech R&D Ltd Chemical compounds
AU2003276648A1 (en) 2002-06-17 2003-12-31 Bristol-Myers Squibb Company Benzodiazepine inhibitors of mitochondial f¿1?f¿0? atp hydrolase and methods of inhibiting f¿1?f¿0? atp hydrolase
AU2003295402A1 (en) 2002-11-06 2004-06-03 Bristol-Myers Squibb Company Acyl guanidine compounds and use thereof
EP1590338B1 (en) 2002-12-04 2009-08-26 Ore Pharmaceuticals Inc. Modulators of melanocortin receptor
DE102004008141A1 (de) 2004-02-19 2005-09-01 Abbott Gmbh & Co. Kg Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren
US20090275099A1 (en) 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20050272723A1 (en) 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
JP4990766B2 (ja) 2004-07-01 2012-08-01 シンタ ファーマシューティカルズ コーポレーション 二置換型ヘテロアリール化合物
WO2007146167A1 (en) 2006-06-09 2007-12-21 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2009036175A2 (en) 2007-09-14 2009-03-19 The Regents Of The University Of Michigan F1f0-atpase inhibitors and related methods
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
KR100982661B1 (ko) 2008-04-22 2010-09-17 전남대학교산학협력단 플라스멥신 ⅱ 활성을 저해하는 화합물을 유효성분으로함유하는 말라리아 예방 및 치료를 위한 약학 조성물 및이를 이용한 말라리아 치료방법
EP2352724B1 (en) 2008-09-11 2015-04-22 The Regents of the University of Michigan Aryl guanidine f1f0-atpase inhibitors and their medical use
US9169199B2 (en) 2010-12-08 2015-10-27 Lycera Corporation Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
ES2591156T3 (es) 2010-12-08 2016-11-25 Lycera Corporation Inhibidores de F1F0-ATPasas de tipo piridonil guanidina y sus usos terapéuticos
CA2820035A1 (en) * 2010-12-08 2012-06-14 Lycera Corporation Cycloalkyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
PL2648511T3 (pl) 2010-12-08 2017-12-29 Lycera Corporation Pirazoliloguanidynowe inhibitory F1F0-ATPaz i ich zastosowania terapeutyczne
WO2013185046A1 (en) 2012-06-08 2013-12-12 Lycera Corporation Saturated acyl guanid1ne for inhibition of f1f0-atpase
US9920012B2 (en) 2012-06-08 2018-03-20 Lycera Corporation Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
EP2866893A4 (en) 2012-06-08 2015-12-23 Lycera Corp HETEROCYCLIC GUANIDINE F1FO ATPASE INHIBITORS
JP2016539993A (ja) 2013-12-10 2016-12-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ Ｎ−置換ピラゾリルグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤及びその治療用途
JP6486364B2 (ja) 2013-12-10 2019-03-20 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ トリフルオロメチルピラゾリルグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤及びその治療用途
US9815791B2 (en) 2013-12-10 2017-11-14 Lycera Corporation Alkylpyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof

Also Published As

Publication number Publication date
BR112016013116A2 (pt) 2017-08-08
US20170354643A1 (en) 2017-12-14
WO2015089149A1 (en) 2015-06-18
MX2016007445A (es) 2016-09-09
CN105899489A (zh) 2016-08-24
IL245930A0 (en) 2016-08-02
US20150183745A1 (en) 2015-07-02
US10085972B2 (en) 2018-10-02
US9266839B2 (en) 2016-02-23
EP3080089A1 (en) 2016-10-19
JP2016539985A (ja) 2016-12-22
CA2931851A1 (en) 2015-06-18
EP3080089A4 (en) 2017-08-23
AU2014363904B2 (en) 2018-10-04
US20160287559A1 (en) 2016-10-06
JP6486364B2 (ja) 2019-03-20
AU2014363904A1 (en) 2016-06-30
US20190175556A1 (en) 2019-06-13
US9707211B2 (en) 2017-07-18
EP3080089B1 (en) 2019-05-08

Similar Documents

Publication Publication Date Title
BR112016013116A8 (pt) inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
CY1122098T1 (el) Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
MX380469B (es) Compuestos heterociclos bicíclicos y sus usos en terapia.
BR112018010464A2 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
MX375706B (es) Compuestos de inhibidor de autotaxina.
SV2016005180A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
MX373187B (es) Terapia de combinación para tratar cáncer.
JOP20200097A1 (ar) معدل مستقبل أندروجين واستخداماته
MX384490B (es) Agentes que inducen apoptosis para el tratamiento de cancer y enfermedades inmunitarias y autoinmunitarias.
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
MX344590B (es) Inhibidores de f1f0-atpasas de tipo pirazolilguanidina y sus usos terapéuticos.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
WO2013185048A3 (en) Heterocyclic guanidine f1f0-atpase inhibitors
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
MX375318B (es) Formas de dosificación y usos terapéuticos de l-4-cloro quinurenina..
MX2017003016A (es) Derivados de piridazinona como inhibidores de las fosfoinositido-3-cinasas.
EA201592012A1 (ru) Применение флагеллина для улучшенной химиотерапии
PH12020500472A1 (en) Autotaxin inhibitor compounds
HK1228393A1 (en) Trifluoromethyl pyrazolyl guanidine f1fo-atpase inhibitors and therapeutic uses thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements